Filibuvir
Filibuvir
Filibuvir (pronounced: /fiːliːbjuːvɪr/) is an experimental antiviral drug that is being studied for the treatment of Hepatitis C. It is a non-nucleoside polymerase inhibitor that was developed by Pfizer.
Etymology
The name "Filibuvir" is derived from the Latin words filum meaning "thread" and buvir which is a short form of "buccal virus", referring to the drug's mechanism of action against viral replication.
Mechanism of Action
Filibuvir works by inhibiting the RNA-dependent RNA polymerase, an enzyme that is essential for the replication of the hepatitis C virus. By blocking this enzyme, Filibuvir prevents the virus from multiplying in the body.
Clinical Trials
Filibuvir has been tested in several clinical trials for its efficacy and safety in patients with chronic hepatitis C. In a Phase 2 trial, Filibuvir was found to be well-tolerated and showed promising antiviral activity.
Related Terms
See Also
External links
- Medical encyclopedia article on Filibuvir
- Wikipedia's article - Filibuvir
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski